Passer au contenu Aller au pied de page
Dabigatran: Benefits, Reviews, Info, Side Effects!
Détails de la prescription
Pradaxa, Pradax, Pradaxal
Dabigatran etexilate
Anticoagulant
Médicaments
Sur ordonnance uniquement
reduced risk of stroke, prevention of blood clots, treatment of deep vein thrombosis, treatment of pulmonary embolism, prevention of recurrent deep vein thrombosis, prevention of recurrent pulmonary embolism
Allergic Reactions, Bleeding, Diarrhea, Dizziness, Fatigue, Heartburn, Indigestion, Liver Enzyme Abnormalities, Nausea, Skin Rash, Stomach Pain
Dabigatran is an anticoagulant medication used to prevent and treat blood clots. The average dosage of dabigatran can vary based on the condition being treated, the patient’s kidney function, and other factors. Typically, for adults: – For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the usual dose is 150 mg taken orally twice daily. – For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and PE, the usual dose is also 150 mg taken orally twice daily after 5-10 days of parenteral anticoagulation. Dosage adjustments may be necessary for patients with renal impairment or those taking certain medications. It’s important for patients to follow their healthcare provider’s instructions regarding dosage. Always consult a healthcare professional for medical advice tailored to individual needs.
Atrial fibrillation, deep vein thrombosis, pulmonary embolism, stroke prevention
Dabigatran has a favorable safety profile.
Aucune interaction signalée
$450 for a 30day supply.

Un résumé de

Dabigatran

Dabigatran is a medication that belongs to a class of drugs known as direct oral anticoagulants (DOACs). It is commonly prescribed to prevent blood clots in patients with conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Dabigatran works by inhibiting the activity of thrombin, a key enzyme in the blood clotting process.

One of the main advantages of dabigatran is that it does not require regular blood monitoring like traditional blood thinners such as warfarin. This can make it a more convenient option for patients who are looking to simplify their medication regimen. However, it is important to take dabigatran exactly as prescribed by your healthcare provider to ensure its effectiveness and minimize the risk of side effects.

Like all medications, dabigatran does come with potential risks. Some patients may experience side effects such as gastrointestinal upset, bleeding, or allergic reactions. It is important to notify your healthcare provider if you experience any unusual symptoms while taking dabigatran.

It is also important to be aware of potential drug interactions with dabigatran. Certain medications, such as antiplatelet drugs or nonsteroidal anti-inflammatory drugs (NSAIDs), can increase the risk of bleeding when taken with dabigatran. Always inform your healthcare provider of all medications you are taking before starting dabigatran.

In conclusion, dabigatran is a valuable medication for preventing blood clots in patients with certain medical conditions. By following your healthcare provider’s instructions and staying informed about potential risks and interactions, you can safely and effectively incorporate dabigatran into your treatment plan.

Avis de non-responsabilité juridique de RxDb

Les informations fournies sur RxDB.net sont fournies à titre informatif uniquement et ne sont pas destinées à remplacer un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours un professionnel de la santé qualifié, tel qu'un médecin ou un pharmacien, pour toute question ou préoccupation concernant votre santé, vos médicaments ou votre état de santé. Vous vous fiez entièrement aux informations fournies sur ce site Web à vos propres risques. RxDB.net ne fournit pas de services médicaux ou pharmaceutiques et n'est pas responsable des décisions prises sur la base des informations contenues dans le présent document.

DERNIÈRE MISE À JOUR DE LA PAGE

0
J'aimerais connaître votre avis, n'hésitez pas à commenter.x
fr_CAFR